For research use only. Not for therapeutic Use.
Vadadustat（Cat No.:I009977）is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor being developed as a new treatment for anemia. It is designed to increase the production of erythropoietin, a hormone that stimulates red blood cell production. By targeting HIF-PH, vadadustat helps regulate the body’s response to low oxygen levels, ultimately addressing anemia. This novel drug offers a potentially convenient and effective option for patients with anemia.
| Catalog Number | I009977 |
| CAS Number | 1000025-07-9 |
| Synonyms | AKB-6548; AKB 6548; AKB6548; PG-1016548; PG 1016548; PG1016548; B-506; B506; Vadadustat;(5-(3-chlorophenyl)-3-hydroxypicolinoyl)glycine |
| Molecular Formula | C14H11ClN2O4 |
| Purity | ≥95% |
| Target | HIF/HIF Prolyl-Hydroxylase |
| Solubility | Soluble in DMSO, not in water |
| Storage | -20°C |
| IUPAC Name | 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| InChI | InChI=1S/C14H11ClN2O4/c15-10-3-1-2-8(4-10)9-5-11(18)13(16-6-9)14(21)17-7-12(19)20/h1-6,18H,7H2,(H,17,21)(H,19,20) |
| InChIKey | JGRXMPYUTJLTKT-UHFFFAOYSA-N |
| SMILES | C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O |
| Reference | </br>1:Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease. Martin ER, Smith MT, Maroni BJ, Zuraw QC, deGoma EM.Am J Nephrol. 2017;45(5):380-388. doi: 10.1159/000464476. Epub 2017 Mar 25. PMID: 28343225 Free Article</br>2:Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH.Kidney Int. 2016 Nov;90(5):1115-1122. doi: 10.1016/j.kint.2016.07.019. Epub 2016 Sep 17. PMID: 27650732 Free Article |
